Follow the HLB stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, HLB has logged 30 public disclosures. Market capitalisation: €304bn. The latest transaction was filed on 16 July 2026 (Other). Among the most active insiders: 진양곤. The full history is openly available.
29
Insider Decl.
n/a
Thresholds
n/a
4 ops.
Buy Volume
n/a
n/a
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,136 of 28,932 companies
17.4
score / 100
Value
19
Quality
16
FCF yld-6.6%
Earn yld-7.1%
EV/EBITDA·
ROE-14%
Gross mgn13%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
HLB is a company in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative treatments and therapeutic solutions.